Drug Combination Details
| General Information of the Combination (ID: C73577) | |||||
|---|---|---|---|---|---|
| Name | Ginsenoside Rg3 NP Info | + | Capecitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CD34 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | 4T1 cells (1*106) were suspended in 0.1 mL of PBS and injected into the mammary fat pad in the right flank of each BALB/c mice. | |||||
| Experimental
Result(s) |
The study demonstrates the feasibility of delivering capecitabine and gensinoside Rg3 in a metronomic chemotherapy regimen, which is proved to be safe, effective, and potentially applicable to clinical treatment. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm. 2008 Oct;23(5):647-53. | |||
